Table 1. Influence of different variables on survival in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy.
| Variables | No. | 3-year OS (%) | P | 3-year DFS (%) |
P | 3-year DMFS (%) | P | 3-year LRFS (%) | P |
|---|---|---|---|---|---|---|---|---|---|
| Age | 0.028 | 0.425 | 0.406 | 0.704 | |||||
| ≤55 | 156 | 90.0 | 75.5 | 82.3 | 95.8 | ||||
| >55 | 154 | 83.4 | 71.8 | 78.0 | 94.1 | ||||
| Sex | 0.515 | 0.584 | 0.724 | 0.262 | |||||
| Male | 207 | 85.6 | 73.6 | 80.0 | 94.3 | ||||
| Female | 103 | 88.8 | 73.9 | 80.4 | 96.5 | ||||
| Tumor location | 0.986 | 0.821 | 0.349 | 0.366 | |||||
| ≤5cm | 169 | 85.2 | 73.6 | 82.2 | 93.5 | ||||
| >5cm | 141 | 88.3 | 73.6 | 77.6 | 96.9 | ||||
| CEA (ng/L) | 0.143 | 0.106 | 0.099 | 0.734 | |||||
| ≤5 | 170 | 90.1 | 78.5 | 84.8 | 94.9 | ||||
| >5 | 140 | 83.5 | 68.7 | 75.4 | 95.4 | ||||
| CA19-9 (U/mL) | 0.003 | 0.001 | 0.039 | 0.686 | |||||
| ≤35 | 257 | 90.0 | 77.1 | 82.8 | 95.0 | ||||
| >35 | 53 | 73.5 | 57.9 | 68.2 | 94.9 | ||||
| Tumor grade | 0.769 | 0.458 | 0.754 | 0.978 | |||||
| I | 43 | 92.1 | 67.9 | 75.1 | 97.1 | ||||
| II | 234 | 87.3 | 74.9 | 81.3 | 94.8 | ||||
| III | 33 | 81.6 | 75.5 | 81.8 | 93.7 | ||||
| Clinical T staging | 0.236 | 0.633 | 0.780 | 0.628 | |||||
| cT2 | 7 | 100 | 85.7 | 85.7 | 100 | ||||
| cT3 | 131 | 89.1 | 74.4 | 78.6 | 95.3 | ||||
| cT4 | 172 | 84.5 | 72.8 | 81.1 | 94.6 | ||||
| Clinical N staging | 0.286 | 0.309 | 0.026 | 0.507 | |||||
| N0 | 83 | 87.2 | 76.9 | 88.3 | 95.4 | ||||
| N1 | 109 | 83.9 | 68.9 | 72.5 | 92.3 | ||||
| N2 | 118 | 88.8 | 75.8 | 81.2 | 97.1 | ||||
| Clinical stage | 0.148 | 0.127 | 0.019 | 0.839 | |||||
| II | 84 | 87.3 | 77.2 | 88.5 | 95.5 | ||||
| III | 226 | 86.4 | 72.2 | 77.0 | 94.9 | ||||
| ypT stage | 0.004 | <0.001 | <0.001 | 0.282 | |||||
| ypT0 | 79 | 93.0 | 82.0 | 92.0 | 94.0 | ||||
| ypT1 | 12 | 91.8 | 100 | 100 | 100 | ||||
| ypT2 | 54 | 94.3 | 88.2 | 94.0 | 100 | ||||
| ypT3 | 140 | 81.1 | 62.8 | 67.9 | 94.6 | ||||
| ypT4 | 25 | 80.0 | 64.0 | 71.2 | 87.5 | ||||
| ypN stage | <0.001 | <0.001 | <0.001 | 0.063 | |||||
| ypN0 | 233 | 92.5 | 80.5 | 87.1 | 97.2 | ||||
| ypN1 | 60 | 71.4 | 54.7 | 61.0 | 90.8 | ||||
| ypN2 | 17 | 79.6 | 47.1 | 51.3 | 85.9 | ||||
| PCR | 0.086 | 0.040 | 0.005 | 0.711 | |||||
| No | 235 | 84.8 | 70.9 | 76.5 | 95.0 | ||||
| Yes | 75 | 92.6 | 82.4 | 91.6 | 95.0 | ||||
| AJCC-TRG | 0.036 | 0.066 | 0.020 | 0.112 | |||||
| TRG0 | 75 | 95.5 | 84.9 | 92.9 | 89.0 | ||||
| TRG1 | 67 | 91.5 | 77.6 | 81.3 | 77.0 | ||||
| TRG2 | 143 | 84.8 | 68.0 | 74.9 | 77.2 | ||||
| TRG3 | 25 | 85.7 | 66.3 | 71.1 | 62.0 | ||||
| Tumor deposits | <0.001 | <0.001 | 0.001 | 0.273 | |||||
| No | 256 | 91.2 | 78.9 | 84.0 | 95.7 | ||||
| Yes | 54 | 66.4 | 49.4 | 61.6 | 91.9 | ||||
| Adjuvant chemotherapy | 0.026 | 0.356 | 0.636 | 0.257 | |||||
| No | 87 | 82.7 | 73.2 | 80.2 | 93.4 | ||||
| Yes | 223 | 88.2 | 75.9 | 80.2 | 95.7 |
Note: OS=overall survival; DFS=disease-free survival; DMFS=distant metastasis free survival; LRFS= local recurrence free survival; PCR=pathological complete response; TRG=tumor regression grade.